Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00403650 · ClinicalTrials.gov registry record · Phase 4
Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension
A Phase 4 study of Pulmonary Arterial Hypertension and Sarcoidosis, sponsored by University of Cincinnati.
- Completed
- Registry status
- Phase 4
- Development phase
- 20
- Enrollment target
- 1
- Study location
NCT00403650: Completed Phase 4 study of Pulmonary Arterial Hypertension and Sarcoidosis, sponsored by University of Cincinnati.
NCT00403650 is a Phase 4 study of Pulmonary Arterial Hypertension and Sarcoidosis that has completed, run by University of Cincinnati. The registered enrollment target is 20 participants, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00403650, a Phase 4 study of Pulmonary Arterial Hypertension and Sarcoidosis, has completed, sponsored by University of Cincinnati.
- COMPLETED
- Registry status
- Phase 4
- Development phase
- 20 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
Conditions Studied
Interventions
- DRUG Iloprost
Study Locations (1)
Ohio
- University of Cincinnati - Cincinnati
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 20 participants |
| Start Date | 2006-11 |
| Est. Completion | 2008-09 |
| Phase | Phase 4 |
What the finished NCT00403650 record still lists
NCT00403650 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 20 participants, a relatively small participant target, below the 462-participant average among 63 other Pulmonary Arterial Hypertension trials with a reported enrollment target (96% lower).
The record links to 2 conditions, with Pulmonary Arterial Hypertension appearing as the primary indexed condition, and to 1 intervention - of which Iloprost is the first listed.
NCT00403650 reports a single indexed study location in Ohio.
Frequently Asked Questions
What is clinical trial NCT00403650 about?
NCT00403650 is a clinical study titled "Inhaled Iloprost for Sarcoidosis-associated Pulmonary Hypertension". This trial will study the treatment of sarcoidosis-associated pulmonary arterial hypertension with inhaled iloprost, a drug approved for primary pulmonary arterial hypertension.
What is the current status of trial NCT00403650?
This trial is currently completed. It is a Phase 4 study. The enrollment target is 20 participants. The study started on 2006-11. Estimated completion is 2008-09.
What conditions does trial NCT00403650 study?
This clinical trial studies the following conditions: Pulmonary Arterial Hypertension, Sarcoidosis.
What interventions are being tested in trial NCT00403650?
The interventions under investigation include: Iloprost (DRUG).
Who is sponsoring clinical trial NCT00403650?
This trial is sponsored by University of Cincinnati, which has 245 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00403650 being conducted?
This trial has 1 study location across Ohio. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Pulmonary Arterial Hypertension
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT00403650's enrollment target sits among peer trials
20 49th of 63 higher than 10 of 63 other Pulmonary Arterial Hypertension trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Pulmonary Arterial Hypertension trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Sotatercept on Central Cardiopulmonary Performance and Peripheral Oxygen Transport During Exercise in Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
A Study of a Mean Pulmonary Artery Pressure-Targeted Approach With Early and Rapid Treprostinil Therapy to Reverse Right Ventricular Remodeling in Participants With Pulmonary Arterial Hypertension
ACTIVE NOT RECRUITING · Phase 4
-
Assess the Efficacy and Safety of Sildenafil When Added to Bosentan in the Treatment of Pulmonary Arterial Hypertension
COMPLETED · Phase 4
-
Transition From Injectable Prostacyclin Medication to Inhaled Prostacyclin Medication
COMPLETED · Phase 4
-
Epoprostenol for Injection in Pulmonary Arterial Hypertension - Extension of AC-066A401
COMPLETED · Phase 4
-
Effect of Selexipag on Daily Life Physical Activity of Patients With Pulmonary Arterial Hypertension.
COMPLETED · Phase 4
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00573339 · 20 participants
Cardiac Magnetic Resonance Imaging (MRI) Normal Reference Control Group Testing
- NCT00692939 · 20 participants · Phase 1
Autologous Stem Cell Transplantation for Crohn's Disease
- NCT00967785 · 20 participants · Phase 1
A Phase I Study of Mozobil in the Treatment of Patients With WHIMS
- NCT01406691 · 20 participants · Phase 4
Light Flashes to Treat Delayed Sleep Phase Disorder (DSPD)
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia